Last reviewed · How we verify
ribavirin with adaptation dose
Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis.
Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis. Used for Chronic hepatitis C, Respiratory syncytial virus infection.
At a glance
| Generic name | ribavirin with adaptation dose |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Nucleoside analog |
| Target | RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to the viral RNA polymerase, preventing the replication of the virus. This leads to a decrease in viral load and an improvement in symptoms.
Approved indications
- Chronic hepatitis C
- Respiratory syncytial virus infection
Common side effects
- Anemia
- Neutropenia
- Thrombocytopenia
Key clinical trials
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (PHASE4)
- RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin (PHASE3)
- High Dose Ribavirin in the Treatment of Chronic Hepatitis C (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |